Image

Care in Multiple Sclerosis (MS)

Care in Multiple Sclerosis (MS)

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This study is structured around three main aims.

In Aim 1, investigators will conduct community-based participatory research (CBPR) to develop culturally tailored methods to assess childhood adversity in multiple sclerosis (MS).

Aim 2 will investigate the impact of childhood adversity on MS outcomes among individuals with relapsing-remitting MS (RRMS), among whom 70% belong to a group historically under-represented in MS research: Black, Hispanic, or poverty-impacted. Aim 2 procedures involve two visits that include a research blood draw and an MRI scan.

In Aim 3, investigators will conduct interviews and surveys to explore environmental and social factors affecting quality of life for minority MS patients.

Eligibility

Inclusion Criteria:

Aim 1 -

  • aged ≥18-29 years
  • diagnosis of RRMS (Fulfill international criteria for relapsing remitting (RRMS))
  • 70% self-identifying as a Black, Hispanic, or poverty-impacted (up to 138% of the federal poverty level) individual,and
  • fluent in English or Spanish.

Aim 2 -

  • aged ≥18-29 years
  • diagnosis of RRMS (Fulfill international criteria for relapsing remitting (RRMS))
  • 70% self-identifying as a Black, Hispanic, or poverty impacted, and
  • fluent reading in English or Spanish
  • Pediatric onset MS (MS onset before age 18 and age at time of enrollment is 18-25) OR adult-onset MS (MS onset at age 18 or older and age at time of enrollment is 19-29)
  • Disease duration below 8 years

Aim 3 -

Aim 3 will enroll the first 20 participants from Aim 2 who meet the following criteria:

  • completed at least 80% of study data in the cross-sectional study/Aim 2.
  • a total of 70% must self-identify as Black, Hispanic, or meet criteria for poverty impacted.
  • interviews will be evenly split between participants with high (top quartile) and low (bottom quartile) of PROMIS-10 scores.

Exclusion Criteria:

  • Primary or Secondary Progressive MS
  • Inability to consent.
  • MS relapse within 30 days prior to study entry
  • Other major neurologic or psychiatric illness

Study details
    Multiple Sclerosis

NCT07011914

NYU Langone Health

1 November 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.